LPCN 1144

Changing the Treatment of NASH

Finding A Solution to Fatty Liver Diseases

Team of Research Scientists Working With Personal Computer, Anal

Targeted For Non-Alcoholic Steatohepatitis (NASH)

LPCN 1144, an oral prodrug of bioidentical testosterone, is being developed as a treatment for pre-cirrhotic non-alcoholic steatohepatitis ("NASH") and recently completed a Phase 2 paired biopsy NASH confirmed clinical study.

Learn About NASH

Expanded Access Policy -Lipocine

Rationale to Target Non-Cirrhotic Male NASH Patients
Association Between Testosterone and Liver Disease
Clinical Evidence of Association Between Testosterone and Liver Disease
LPCN 1144: Androgen Receptor Agonist
LPCN 1144: A Differentiated NASH Treatment Candidate
Screen Shot 2021-10-07 at 3.18.47 PM
Screen Shot 2021-10-07 at 3.22.01 PM
Screen Shot 2021-10-07 at 3.22.54 PM
Screen Shot 2021-10-07 at 3.27.10 PM
Screen Shot 2021-10-07 at 3.28.13 PM
Screen Shot 2021-10-07 at 3.28.44 PM
Screen Shot 2021-10-07 at 3.29.32 PM
Screen Shot 2021-10-07 at 3.30.06 PM
Screen Shot 2021-10-07 at 3.30.38 PM
Screen Shot 2021-10-07 at 3.31.35 PM
Screen Shot 2021-10-07 at 3.31.58 PM
LFS was an open-label, multi-center single-arm 16-week study (N=36) with LPCN 1144 in hypogonadal males
Slide 3

*LF = Liver Fat

Meaningful Relative Liver Fat % Change and Responder Rate
slide 4

* Responder rate for relative change is % of patients with at least 30% for relative change from baseline. 

Liver Fat-Based Subject Distribution at Each Visit
Longer Therapy Improved Proportion of Subjects with Disease Resolution
Slide 5

Innovative Pharmaceutical Products

ENHANCING HEALTH & IMPROVING PATIENT COMPLIANCE

Become Part of The Change
Scroll to Top